Roger Adsett Sells 7,482 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 7,482 shares of the firm’s stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $67.81, for a total value of $507,354.42. Following the completion of the sale, the chief operating officer now owns 138,600 shares of the company’s stock, valued at approximately $9,398,466. This represents a 5.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Roger Adsett also recently made the following trade(s):

• On Wednesday, May 14th, Roger Adsett sold 1,925 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total value of $126,299.25.

Insmed Stock Up 2.5%

INSM stock opened at $67.22 on Friday. The stock has a 50-day simple moving average of $71.68 and a two-hundred day simple moving average of $73.12. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The firm has a market capitalization of $12.22 billion, a PE ratio of -12.03 and a beta of 0.84.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business’s revenue was up 22.9% compared to the same quarter last year. During the same quarter last year, the business posted ($1.06) EPS. On average, equities analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Insmed

Several hedge funds have recently added to or reduced their stakes in INSM. Park Avenue Securities LLC increased its holdings in shares of Insmed by 42.1% in the fourth quarter. Park Avenue Securities LLC now owns 7,955 shares of the biopharmaceutical company’s stock worth $549,000 after buying an additional 2,358 shares during the period. Atomi Financial Group Inc. increased its stake in Insmed by 6.6% in the 4th quarter. Atomi Financial Group Inc. now owns 24,774 shares of the biopharmaceutical company’s stock worth $1,710,000 after purchasing an additional 1,526 shares during the period. Nisa Investment Advisors LLC lifted its position in Insmed by 5.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 183 shares during the last quarter. Avior Wealth Management LLC purchased a new stake in shares of Insmed during the fourth quarter valued at approximately $157,000. Finally, Blue Trust Inc. grew its holdings in shares of Insmed by 25.7% in the fourth quarter. Blue Trust Inc. now owns 2,462 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 503 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Truist Financial increased their target price on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a report on Friday, February 21st. JPMorgan Chase & Co. raised their price objective on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday, February 7th. Morgan Stanley boosted their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Wells Fargo & Company lifted their target price on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $100.00 price target on shares of Insmed in a research report on Wednesday, March 19th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $94.63.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.